Sacubitril-Valsartan 49-51Mg Oral Tablet for Heart Failure
Study Summary
This trial is testing if therapies to reduce aldosterone and increase BNP levels may help improve heart health for people with HIV.
- Diastolic Heart Failure
- HIV/AIDS
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Is there still room for new participants in this clinical trial?
"That is correct, the listing on clinicaltrials.gov confirms that this study is currently seeking patients. The trial was originally posted on September 11th 2020 and was updated most recently on July 27th 2022. Only 50 participants are needed for this single-site study."
How can I become a part of this research?
"The prerequisites for this study are that patients must have AIDS and be between 40-70 years old. Out of the total pool of 50 participants, researchers are looking to enroll those who match these qualifications."
What health conditions is Sacubitril-Valsartan 49-51Mg Oral Tablet most effective in alleviating?
"Patients with left ventricular dysfunction, uncontrolled hypertension, and essential hypertension can be treated effectively using Sacubitril-Valsartan 49-51Mg Oral Tablets."
Is the lower age limit for this trial set at 18 years old?
"According to the eligibility requirements, patients must be between 40 and 70 years old in order to enroll. Out of 885 total clinical trials, this is the 48th trial for patients under 18 and the 839th for patients over 65."
Are there similar drugs to Sacubitril-Valsartan 49-51Mg Oral Tablet that have been studied in clinical trials?
"There are currently 39 ongoing clinical trials studying the effects of Sacubitril-Valsartan 49-51Mg Oral Tablet. Of those, 8 are in the third and final phase. The majority of research locations for this treatment are based in Montreal, Quebec; however, there are a total of 812 sites running studies worldwide."
Are there any dangers associated with taking Sacubitril-Valsartan 49-51Mg Oral Tablet?
"While there is limited data on the efficacy of Sacubitril-Valsartan, it has been deemed safe in Phase 2 trials and given a score of 2."
How many people are trialing this medication?
"Yes, the trial is currently enrolling patients. According to information on clinicaltrials.gov, the study was originally posted on September 11th 2020 and was last updated July 27th 2022. They are looking for 50 participants at 1 site."